A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate if treatment with AZD9668 for 28 days is
effective in treating Bronchiectasis (Brx) and if so how it compares to placebo (a substance
which does not have any action).